CDW Holding has officially launched its skincare product, YOSHIMI Night Cream X, an anti-aging cream that will be available for sale from 1 October 2021 through YOSHIMI JAPAN’s online store. YOSHIMI currently ships and sells to customers in Japan, China, Hong Kong, and Singapore, with more destinations to be added in the future. Customers in Japan can also purchase the product in person from beauty retailer NewMe’s flagship store in Fukuoka, Japan.
About The Cream
Night Cream X contains 38 different kinds of herbs, flower and fruit extracts, and active ingredients like fullerene and vitamin B32, which have shown to have anti-aging effects on the skin. However, the unique ingredient which sets the skincare cream apart in a crowded market is pterostilbene glycoside – an antioxidant jointly developed by CDW and Professor Emeritus Hiroki Hamada from the Okayama University of Science, after discovering its tremendous potential in skincare applications, and for which CDW has obtained a patent in Japan and South Korea.
Pterostilbene is a type of antioxidant commonly found in grapes, berries, and other plants, and becomes water-soluble when glycosylated, allowing it to be absorbed better and remain in the skin longer, thus maximising its anti-aging effects.
“YOSHIMI Night Cream X is an important development milestone, both for the Company and the industry. We are the first company to harness the tremendous potential of pterostilbene glycoside in the skincare and cosmetic industry.”, said Yoshikawa Makoto, the Chairman and Chief Executive Officer of CDW.
Clinical Tests
A study by Japanese skincare giant, Cosmo Beauty, on a prototype of the pterostilbene glycoside cream showed it improved wrinkles by 20% on average, after four weeks of daily use. This was over three times more effective compared to another leading Japanese brand’s wrinkle cream, which only saw a 6% improvement on average.
“Type 4 collagen levels typically decrease with aging, so the compound’s ability to stimulate its production makes it especially effective in combating sagging, wrinkles, and dark spots in cream-based cosmetics and skincare products”, says Professor Emeritus Hiroki Hamada, lead researcher of the project.
Professor Hamada was awarded the Uchiyama Yuzo Science and Technology Award in 2010 and the Japanese Society for Plant Cell and Molecular Biology Technology Award in 2011. He first published two research papers documenting the collagen-boosting and skin lightening effects of pterostilbene glycoside in 2016.
Market Size
The global anti-aging market was valued at approximately US$44.1 billion in 2020, and is expected to grow at a compounded annual growth rate (CAGR) of 6.1% to reach a revenue of US$64 billion in 2026. Asia Pacific is leading the growth as both developed and developing countries increase their spending on cosmetics. The Asia Pacific anti-aging cosmetics market is expected to grow at a CAGR of 8.31% in terms of revenue from 2019 to 2027. Asian countries are also among the largest markets for cosmetics and personal care products worldwide, with particularly well-developed markets including Japan, Australia, Hong Kong, China and South Korea.
In Japan alone, the anti-aging beauty cosmetics market in 2021 is expected to grow to JPY 739.4 billion (up 3.5% in 2020) as more consumers embrace anti-aging and antiwrinkle skincare needs. There has been a large shift to support the high-end segment targeting middle-aged and older age groups who strongly prefer luxury products. In addition, digital marketing like livestream sales has further stimulated demand, with more young users of beauty products in their 20s and 30s.
————
CDW Holding Limited (the “Company” and together with its subsidiaries, the “Group”) is a Japanese-managed precision components specialist serving the global market focusing on the production and supply of niche precision components for digital instrument panels in the automobile industry, notebook computers, consumer and information technology equipment, office equipment and electrical appliances, and an original equipment manufacturer. The Group is headquartered in Hong Kong and has operations in Japan, China, South Korea, Thailand and the Philippines. The Company has been identifying new businesses to invest in with the potential for growth and entered as part of its diversification strategy and has made forays into the Life Sciences sector since 2016. The Company’s aim for its Life Sciences business is to identify research-driven yet commercialisable projects that can have a positive impact on the quality of human life.
